Chimeric Therapeutics Says CDH17 Granted FDA Orphan Drug Designation For Gastric Cancer
ReutersDec 8, 2025 12:55 AM
Dec 8 (Reuters) - Chimeric Therapeutics Ltd CHM.AX:
CDH17 GRANTED FDA ORPHAN DRUG DESIGNATION FOR GASTRIC CANCER
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Federal Reserve's December Rate Cut: Inevitable? Bitcoin's Next Move: $100K or New Low?
While a 25-basis point Federal Reserve rate cut in December is widely anticipated, market sentiment remains split on Bitcoin's future price trajectory.TradingKey
13 hours ago
Fed's December Rate Cut Almost Certain, But Santa Claus Rally Unlikely
As the U.S. stock market heads into the final month of 2025, investors are beginning to anticipate a "Santa Claus Rally." However, whether this year's rally will materialize remains uncertain, as the Federal Reserve's December FOMC meeting could dictate the direction of U.S. equities.TradingKey
14 hours ago
Intel Stock Rally Explained: What’s Driving INTC Higher and Should You Buy It Now?
TradingKey - Intel (NASDAQ: INTC) shares have surged strongly from multi-year lows, prompting significant investor attention: What's driving this rare rally—fundamentals or market sentiment? Is there further upside, and is now the optimal time to invest?TradingKey
18 hours ago
GameStop: From Epic Short Squeeze to Q3 Earnings, Where Does This Meme Stock Go Next?
TradingKey – GameStop 2021 epic short squeeze to today’s earnings recovery, this legacy game retailer is betting on collectibles and geek-culture transformation while, before its Q3 report, options flows and sentiment once again push Gamestop’s meme premium into spotlight.TradingKey
Fri, Dec 5
Why Did Strategy's Stock Price Plummet? Can MSTR Reach $1,000?
MicroStrategy (MSTR) stock, despite pressures from Bitcoin volatility and its weak core business, represents the most leveraged investment in a Bitcoin bull market. The company's stock path to $1,000 largely depends on Bitcoin's market performance. Major institutions, including Standard Chartered anTradingKey
Thu, Dec 4
Tradingkey
